Literature DB >> 25316487

Fewer cancer reoperations for medullary thyroid cancer after initial surgery according to ATA guidelines.

Hans H G Verbeek1, Johannes A A Meijer, Wouter T Zandee, Kelvin H Kramp, Wim J Sluiter, Johannes W Smit, Job Kievit, Thera P Links, John Th M Plukker.   

Abstract

BACKGROUND: Surgery is still the only curative treatment for medullary thyroid cancer (MTC). We evaluated clinical outcome in patients with locoregional MTC with regard to adequacy of treatment following ATA guidelines and number of sessions to first intended curative surgery in different hospitals.
METHODS: We reviewed all records of MTC patients (n = 184) treated between 1980 and 2010 in two tertiary referral centers in the Netherlands. Symptomatic MTC (palpable tumor or suspicious lymphadenopathy) patients without distant metastasis were included (n = 86). Patients were compared with regard to adequacy of surgery according to ATA recommendations, tumor characteristics, number of local cancer reoperations, biochemical cure, clinical disease-free survival (DFS), overall survival (OS), and complications.
RESULTS: Adherence to ATA guidelines resulted in fewer cancer-related reoperations (0.24 vs. 0.60; P = 0.027) and more biochemical cure (40.9 vs. 20 %; P = 0.038). Surgery according to ATA-guidelines on patients treated in referral centers was significantly more often adequate (59.2 vs. 26.7 %; P = 0.026). Tumor size and LN+ were the most important predictors for clinical recurrence [relative risk (RR) 4.1 (size > 40 mm) 4.1 (LN+) and death (RR 4.2 (size > 40 mm) 8.1 (LN+)].
CONCLUSIONS: ATA-compliant surgery resulted in fewer local reoperations and more biochemical cure. Patients in referral centers more often underwent adequate surgery according to ATA-guidelines. Size and LN+ were the most important predictors for DFS and OS.

Entities:  

Mesh:

Year:  2014        PMID: 25316487     DOI: 10.1245/s10434-014-4115-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Outcomes of surgery and postoperative radiation therapy in managing medullary thyroid carcinoma.

Authors:  Andries H Groen; Thomas H Beckham; Thera P Links; Debra A Goldman; Eric J Sherman; Michael M Tuttle; Hendrik P Bijl; Richard J Wong; John Th M Plukker; Nancy Y Lee
Journal:  J Surg Oncol       Date:  2019-11-16       Impact factor: 3.454

2.  Prognostic value of LODDS in medullary thyroid carcinoma based on competing risk model and propensity score matching analysis.

Authors:  Zhe Xu Cao; Xin Weng; Jiang Sheng Huang; Xia Long
Journal:  Updates Surg       Date:  2022-07-12

3.  National Trends in the Surgical Treatment of Non-advanced Medullary Thyroid Cancer (MTC): An Evaluation of Adherence with the 2009 American Thyroid Association Guidelines.

Authors:  Eun Hae Estelle Chang; Waseem Lutfi; Joseph Feinglass; Alexandra Eudokia Reiher; Tricia Moo-Young; Mihir Kiran Bhayani
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

4.  Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma.

Authors:  Eric J Kuo; Shonan Sho; Ning Li; Kyle A Zanocco; Michael W Yeh; Masha J Livhits
Journal:  JAMA Surg       Date:  2018-01-01       Impact factor: 14.766

5.  A Genomic Alternative to Identify Medullary Thyroid Cancer Preoperatively in Thyroid Nodules with Indeterminate Cytology.

Authors:  Richard T Kloos; Robert J Monroe; S Thomas Traweek; Richard B Lanman; Giulia C Kennedy
Journal:  Thyroid       Date:  2016-04-22       Impact factor: 6.568

6.  Prognosis of radiotherapy in medullary thyroid carcinoma patients without distant metastasis.

Authors:  Shaojun Huang; Jiana Zhong; Zhen Zhang; Rongping Chen; Jitong Li; Jia Sun; Hong Chen
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.